Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Celladon Corporation Appoints Michael Narachi as Chairman of the Board of Directors



  Celladon Corporation Appoints Michael Narachi as Chairman of the Board of
                                  Directors

PR Newswire

SAN DIEGO, Oct. 18, 2013

SAN DIEGO, Oct. 18, 2013 /PRNewswire/ -- Celladon Corporation, a
clinical-stage biotechnology company focused on developing novel therapies by
applying its leadership position in the field of SERCA enzymes, today
announced that it has appointed Michael Narachi as Chairman of the Board of
Directors.

Michael currently serves as President and Chief Executive Officer of Orexigen
Therapeutics, Inc. Michael has 29 years of biotechnology and pharmaceutical
experience across a broad range of functions including clinical development,
commercialization, strategic business development and planning. Prior to
joining Orexigen, Michael served as Chairman, Chief Executive Officer and
President of Ren Pharmaceuticals, Inc., a private biotechnology company and
Executive Chairman of the Board of Naryx Pharma, Inc., a private
pharmaceutical company. In 2004, Narachi retired as an officer and Vice
President and General Manager of Amgen's Anemia Business. Throughout his 20
years at Amgen, Michael held various positions including: Product Development
Team Leader for NEUPOGEN; Director of Clinical Operations in Thousand Oaks,
Calif., and Cambridge, U.K.; Vice President of Development and Representative
Director for Amgen Japan; Head of Corporate Strategic Planning; Chief
Operations Officer of Amgen BioPharma; and Vice President, Licensing and
Business Development. He is also Chairman of AMAG Pharmaceuticals, Inc. and a
member of the Board of Directors at the Biotechnology Industry Organization
(BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Krisztina Zsebo, Ph.D., President and Chief Executive Officer of Celladon,
said "Michael's appointment brings to the Board over two decades of broad
experience in product development and commercial operations at preeminent
biotechnology companies. We look forward to working with him in his new
capacity as Chairman."

About Celladon
We are a clinical-stage biotechnology company applying our leadership position
in the field of calcium dysregulation by targeting SERCA enzymes to develop
novel therapies for diseases with tremendous unmet medical needs.
Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of
enzymes that play an integral part in the regulation of intra-cellular calcium
in all human cells. Calcium dysregulation is implicated in a number of
important and complex medical conditions and diseases, such as heart failure,
diabetes and neurodegenerative diseases. Our therapeutic portfolio for
diseases characterized by SERCA enzyme deficiency includes both gene therapies
and small molecule compounds. MYDICAR, our most advanced product candidate,
uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient
in patients with heart failure. In a 39-patient randomized, double-blind,
placebo-controlled Phase 2a trial in patients with systolic heart failure,
which we refer to as CUPID 1, MYDICAR was found to be safe and well-tolerated,
reduced heart failure-related hospitalizations, improved patients' symptoms,
quality of life and serum biomarkers, and improved key markers of cardiac
function predictive of survival, such as end systolic volume. Based on these
results, as well as our previous preclinical studies and clinical trials, we
have advanced MYDICAR to a randomized, double-blind, placebo-controlled
international Phase 2b trial in patients with systolic heart failure, which we
refer to as CUPID 2. We expect to complete enrollment of CUPID 2 in the first
half of 2014 and announce results from this trial in mid-2015.

SOURCE Celladon Corporation

Contact: Fredrik Wiklund, Vice President, Corporate Development and Investor
Relations, +1- 858-432-7215, fwiklund@celladon.net
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement